September 16, 2009 — Cancer therapies are increasingly being tailored to fit the genetic profile of the patient, but new research suggests that human epidermal growth-factor receptor (HER)2 gene ...

Changes to testing guidelines have doubled the number of patients who test positive for HER2, a protein used to diagnose breast cancer, according to a study published by Mayo Clinic researchers in the ...

Trastuzumab deruxtecan (T-DXd) has redefined the therapeutic landscape for breast cancer since its approval in 2019. Correspondingly, the relevance of HER2 testing beyond the traditional dichotomy of ...

The HER2-low and HER2-ultralow breast cancer subtype designations have led to a changed landscape in HER2-directed therapies, as well as a desire for more sensitive assays that may better quantify ...

"Medical Journeys" is a set of clinical resources reviewed by physicians, meant for the medical team as well as the patients they serve. Each episode of this journey through a disease state contains ...

Blood test for breast cancer patients will be performed by Biocept and analyzed by Clarient. Biocept and Clarient have entered a collaboration to commercialize a blood test for circulating tumor cells ...

Biomarkers are measurable indicators that can be tested to reveal important details about a cancer. Information about these biomarkers can help guide the best treatment for you, predict your response ...

Pathological analysis of tumor microenvironmental features using deep learning to predict survival of colon carcinomas. A prospective, cross-sectional, multicentre study to evaluate the clinical ...

All patients with breast cancer who may be candidates for antibody-drug conjugate therapy should undergo HER2 testing to determine eligibility for Enhertu (fam-trastuzumab deruxtecan-nxki) — an agent ...